SCPS (Scopus BioPharma) Total Tax Payable: $0.00 Mil (As of Jun. 2023)


What is Scopus BioPharma Total Tax Payable?

Scopus BioPharma SCPS Total Tax Payable is $0.00 Mil as of Jun. 2023.

Scopus BioPharma's Total Tax Payable for the quarter that ended in Jun. 2023 was $0.00 Mil.

Scopus BioPharma Total Tax Payable Related Terms

Scopus BioPharma Total Tax Payable Historical Data

* Premium members only.

The historical data trend for Scopus BioPharma's Total Tax Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Scopus BioPharma Total Tax Payable Chart

Scopus BioPharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Total Tax Payable
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Scopus BioPharma Quarterly Data
Jun18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Total Tax Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Scopus BioPharma Total Tax Payable Calculation

Total Tax Payable is the taxes liability owed to federal, state, and local tax authorities. It is the carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes.

Frequently Asked Questions Learn more about Total Tax Payable →
What does a Total Tax Payable of $0.00 Mil mean?
Scopus BioPharma (SCPS) has a Total Tax Payable of $0.00 Mil as of Jun. 2023. Tax Payable is the taxes liability owed to federal, state, and local tax authorities. View historical data on Scopus BioPharma and its competitors.
Is Scopus BioPharma's Total Tax Payable too high?
Scopus BioPharma's current Total Tax Payable is $0.00 Mil.
How does Scopus BioPharma's Total Tax Payable compare to AMPE and DRMA?
Scopus BioPharma's Total Tax Payable of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Tax Payable for a Biotechnology company?
A good Total Tax Payable depends on the Biotechnology industry context. However, Total Tax Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Tax Payable mean?
A high Total Tax Payable can signal that a stock is expensive relative to its fundamentals. Tax Payable is the taxes liability owed to federal, state, and local tax authorities. View historical data on Scopus BioPharma and its competitors. Scopus BioPharma's current Total Tax Payable is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scopus BioPharma stock overvalued right now?
Scopus BioPharma (SCPS) has a current Total Tax Payable of $0.00 Mil. The current Total Tax Payable is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Tax Payable calculated?
Total Tax Payable is calculated from a company's financial statements. For Scopus BioPharma (SCPS), the current Total Tax Payable is $0.00 Mil as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Scopus BioPharma Business Description

Address 420 Lexington Avenue, Suite 300, New York, NY, USA, 10170
Scopus BioPharma Inc a biotechnology company focused on developing therapeutics targeting the endocannabinoid system. The endocannabinoid system is comprised of chemical compounds, or cannabinoids, that interact with cannabinoid receptors which are located throughout the body. Its product candidate comprises CO-sTiRNA, which is a STAT3 inhibitor gene therapy and MRI-1867.